HOCPY Quote, Financials, Valuation and Earnings

Healios KK has a net margin of 27.29% compared to Hoya's net margin of -107.23%. Hoya's return on equity of 20.48% beat Healios KK's return on equity of -137.21%.

Hoya has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Hoya has higher upside potential than Healios KK, analysts believe Hoya is more attractive than Healios KK.

Hoya has a beta of 0.817, which suggesting that the stock is 18.282% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hoya has a quarterly dividend of $0.30 per share corresponding to a yield of 0.57%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hoya pays 21.38% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Hoya's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hoya quarterly revenues are $1.4B, which are larger than Healios KK quarterly revenues of $3.2M. Hoya's net income of $379.2M is higher than Healios KK's net income of -$3.4M. Notably, Hoya's price-to-earnings ratio is 39.91x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoya is 8.07x versus 22.75x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of 27.29% compared to Hoya's net margin of -5.57%. Hoya's return on equity of 20.48% beat PeptiDream's return on equity of 34.66%.

Hoya has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Hoya has higher upside potential than PeptiDream, analysts believe Hoya is more attractive than PeptiDream.

Hoya has a beta of 0.817, which suggesting that the stock is 18.282% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.804, suggesting its less volatile than the S&P 500 by 19.554%.

Hoya has a quarterly dividend of $0.30 per share corresponding to a yield of 0.57%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hoya pays 21.38% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Hoya's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hoya quarterly revenues are $1.4B, which are larger than PeptiDream quarterly revenues of $36.8M. Hoya's net income of $379.2M is higher than PeptiDream's net income of -$2.1M. Notably, Hoya's price-to-earnings ratio is 39.91x while PeptiDream's PE ratio is 21.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoya is 8.07x versus 7.43x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of 27.29% compared to Hoya's net margin of 12.96%. Hoya's return on equity of 20.48% beat Nxera Pharma's return on equity of -5.58%.

Hoya has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Hoya has higher upside potential than Nxera Pharma, analysts believe Hoya is more attractive than Nxera Pharma.

Hoya has a beta of 0.817, which suggesting that the stock is 18.282% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.401, suggesting its less volatile than the S&P 500 by 59.86%.

Hoya has a quarterly dividend of $0.30 per share corresponding to a yield of 0.57%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hoya pays 21.38% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Hoya's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hoya quarterly revenues are $1.4B, which are larger than Nxera Pharma quarterly revenues of $62.4M. Hoya's net income of $379.2M is higher than Nxera Pharma's net income of $8.1M. Notably, Hoya's price-to-earnings ratio is 39.91x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoya is 8.07x versus 2.79x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of 27.29% compared to Hoya's net margin of 7.83%. Hoya's return on equity of 20.48% beat Takeda Pharmaceutical's return on equity of 4.01%.

Hoya has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $16.06 which suggests that it could grow by 19.98%. Given that Takeda Pharmaceutical has higher upside potential than Hoya, analysts believe Takeda Pharmaceutical is more attractive than Hoya.

Hoya has a beta of 0.817, which suggesting that the stock is 18.282% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.642%.

Hoya has a quarterly dividend of $0.30 per share corresponding to a yield of 0.57%. Takeda Pharmaceutical offers a yield of 4.66% to investors and pays a quarterly dividend of $0.33 per share. Hoya pays 21.38% of its earnings as a dividend. Takeda Pharmaceutical pays out 199.34% of its earnings as a dividend. Hoya's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

Hoya quarterly revenues are $1.4B, which are smaller than Takeda Pharmaceutical quarterly revenues of $7.9B. Hoya's net income of $379.2M is lower than Takeda Pharmaceutical's net income of $619.7M. Notably, Hoya's price-to-earnings ratio is 39.91x while Takeda Pharmaceutical's PE ratio is 21.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoya is 8.07x versus 1.40x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.